Phibro Animal Health | PAHC - Selling And Administration Expenses


Phibro Animal Health reported $78.32M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Align Technology USD 465.34M 23.67M Mar/2026
ANI Pharmaceuticals USD 73.66M 9.14M Mar/2026
Assertio Holdings USD 16.73M 1.66M Sep/2024
Aurora Cannabis CAD 40.62M 1.17M Dec/2025
Bristol-Myers Squibb USD 1.62B 564M Mar/2026
Canopy Growth CAD 28.9M 636K Dec/2025
Corcept Therapeutics USD 128.04M 13.3M Mar/2026
Eli Lilly USD 2.93B 198M Mar/2026
Henry Schein USD 809M 1000K Mar/2026
Idexx Laboratories USD 299.85M 24.18M Mar/2026
Knight Therapeutics CAD 35.45M 4.43M Dec/2025
Merck USD 2.67B 180M Mar/2026
Nektar Therapeutics USD 10.17M 10.17M Dec/2025
Pacira USD 83.88M 7.99M Mar/2026
Phibro Animal Health USD 78.32M 10.24M Dec/2025
Prestige Brands USD 30.28M 606K Mar/2026
Supernus Pharmaceuticals USD 118.23M 4.16M Mar/2026
Zoetis USD 588M 31M Mar/2026